TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06030011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NYU Electronic Patient Visit Assessment (ePVA)
Description: The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
Study: NCT06335121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER Up strategies -
Description: Clinics will implement adapted POWER Up intervention strategies when a patient is flagged as PrEP eligible.
Study: NCT05985317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane over BMAC/bovine graft in sinus lift
Description: Collagen membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF membrane over BMAC/bovine graft in sinus lift
Description: PRF membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
Study: NCT06163079

Intervention type: BEHAVIORAL
Intervention: No intervention
Description: No intervention. This is a retrospective study. Data will be collected from routine consultations Will be collectad the following datas : Number and evolution of requests, age, background, infertility timing, parenthood context, Appointment time, ART timing, Type of ART, ART outcome, Outcome time

Intervention type: BEHAVIORAL
Intervention: No intervention
Description: No intervention. This is a retrospective study. Data will be collected from routine consultations Will be collectad the following datas : Number and evolution of requests, age, background, infertility timing, parenthood context, Appointment time, ART timing, Type of ART, ART outcome, Outcome time
Study: NCT04924868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
Study: NCT05340140

Intervention type: DIAGNOSTIC_TEST
Intervention: deep learning model
Description: deep learning model developed by computer science expert and based on convolution neural network , and trained by our datasets.
Study: NCT05314023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
Study: NCT04899908

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Focused radiation beams to treat tumors

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Focused radiation beams to treat tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX gadolinium-based nanoparticles
Description: Intravenous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion
Study: NCT05314023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
Study: NCT05793619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 301) to (816-v1 355) every week
Description: Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (816-v1 301) to (816-v1 355) every two weeks
Description: Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study: NCT06035107

Intervention type: DIAGNOSTIC_TEST
Intervention: Radar blood pressure device
Description: The radar blood pressure device will be compared with other traditional blood pressure measurement methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radar blood pressure device
Description: The radar blood pressure device will be compared with other traditional blood pressure measurement methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radar blood pressure device
Description: The radar blood pressure device will be compared with other traditional blood pressure measurement methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radar blood pressure device
Description: The radar blood pressure device will be compared with other traditional blood pressure measurement methods.
Study: NCT05187949

Intervention type: OTHER
Intervention: Mixed-method approach
Description: Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)

Intervention type: OTHER
Intervention: Mixed-method approach
Description: Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
Study: NCT06038812

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-surgical periodontal treatment
Description: performing scaling and root planning using ultrasonic device and manual curettes
Study: NCT04762030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab Anlotinib Carboplatin Nab-paclitaxel
Description: Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered.
Study: NCT05187949

Intervention type: OTHER
Intervention: Mixed-method approach
Description: Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
Study: NCT05913856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
Study: NCT05656443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171/Ritonavir
Description: dose of 150 mg GST-HG171 with 100 mg ritonavir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04718506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises \[squat, bench press, deadlift and bench pull\]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controls
Description: Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
Study: NCT06378242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin for injection
Description: Intravesical instiliations into the bladder
Study: NCT04713137

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol
Description: 50g erythritol dissolved in 300mL tap water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 33.5g sucrose dissolved in 300mL tap water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucralose
Description: 0.0558g sucralose dissolved in 300mL tap water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300mL tap water.
Study: NCT05317052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage group
Description: Massage and music therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage group
Description: Massage and music therapy
Study: NCT04971226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Comes in 100 mg and 400 mg tablets and taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Comes in 150 mg capsules and taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib
Description: Comes in 100 mg and 400 mg tablets and taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Comes in 70 mg and 100 mg tablets and taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Comes in 40 mg tablets and taken orally
Study: NCT05998265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetMe rehabilitation
Description: Home based rehabilitation program with real time biofeedback using a connected device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Conventional physiotherapy as prescribed by the neurologists
Study: NCT06355622

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Characterization of pain
Description: Standardized scales and questionnaires to detect and characterize pain, blood sample for pain biomarkers, neurophysiological tests
Study: NCT05792202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfracture procedure
Description: double raw repair combined with microfracture procedure which promotes tendon healing by releasing growth factors

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: only double raw repair
Description: the double raw repair was used to repair the tendon tear
Study: NCT04975802

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 oz (296 ml) cherry flavored still beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffeeberry
Description: 10 oz (296 ml) cherry flavored still beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffeeberry
Description: 10 oz (296 ml) cherry flavored still beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 10 oz (296 ml) cherry flavored still beverage
Study: NCT04532788

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Customized crosslinking
Description: In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard crosslinking
Description: In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States).
Study: NCT06493266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurolinguistic programmino
Description: In this randomized controlled study, the group of patients with an indication for colposcopy in the Gynecological Oncology Department of Şanlıurfa Training and Research Hospital, Department of Gynecology and Obstetrics, will be divided into two groups and NLP training will be given before colposcopy in a double-blind manner, and after colposcopy, VAS (visual pain scale), fear of pain scale will be given. 3, evaluation will be made using the pain catastrophizing scale. NLP training will be given for approximately 20 minutes, and the group that will not receive NLP training will remain silent for 20 minutes. The results will be compared.
Study: NCT05790226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentry System
Description: any labelling or contrast agents. The Sentry System uses the Sentry Probe, a flexible cable that terminates in a stylus that delivers a small beam of light to the surface of the excised tissue specimen and collects the Raman spectrum of the light coming back from the same area of the specimen.
Study: NCT05995613

Intervention type: DEVICE
Intervention: MABOS
Description: The novel pulse oximeter (MABOS) will be placed to acquire two biometrics: blood oxygen saturation and epidermal melanin concentration.

Intervention type: DEVICE
Intervention: Nonin PureSat
Description: An FDA approved pulse oximeter will be placed to acquire blood oxygen saturation.
Study: NCT06656767

Intervention type: OTHER
Intervention: No intervention
Description: This study utilises pre-collected samples only.
Study: NCT06657235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care Program
Description: Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. The participant will be monitored continuously while on the platform and up-to-date reports will be shared with the participant's relevant care providers every 30 days or as needed. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care Program
Description: Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. The participant will be monitored continuously while on the platform and up-to-date reports will be shared with the participant's relevant care providers every 30 days or as needed. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.
Study: NCT06656442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: an anti-ischemic medication.
Study: NCT06656208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pubic symphysis manipulation
Description: Manipulation was applied in the crook lying position with 5 repetitions hold for 10 sec and ask the patient to apply max. Contraction in Abduction and then relax. Whereas, the therapist applies a rapid stretch to a new barrier and is held for 10 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional sacroiliac treatment
Description: Mobilization was applied in prone lying position on sacroiliac joint, 30 Oscillations per set for 15 seconds, 3 sets on effected side.
Study: NCT06620107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive high frequency oscillation ventilation
Description: cases of group A extubated on NHFOV, and it will be provided by CNO, Medin device, Germany) via binasal prongs with the following parameters:~* MAP of 6 cmH2O and will be titrated targeting a FiO2 ≤ 25-30%, maximum FiO2 will be 40% and target oxygen saturation will be 90-95%.~* Frequency of 8 Hz and can be changed within the range of 8-12 Hz.~* Amplitude of 7 cmH2O and can be titrated within the range of 7-10 cmH2O according to PaCO2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: NIPPV will be provided by any type of neonatal ventilator available in the unit via binasal prongs starting with the following parameters:~* Positive end expiratory pressure (PEEP) of 5 cmH2O and can be titrated to 8 cmH2O according to the oxygenation .~* Peak inspiratory pressure (PIP) of 15 cmH2O and can be titrated to 25 cmH2O ,according to oxygenation , PaCO2 level and the chest expansion .~* FiO2 ≤ 25-30% and can be increased to 40 % maximally targeting oxygen saturation of 90-95% .~* Inspiratory time of 0.40-0.50 s .~* Rate of 30 bpm and can be increased to maximum 50 bpm .~* Synchronization will not be applied.
Study: NCT06657443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Session
Description: Introductions, explanation of the purpose and content of the project, realisation of the pre-test application. Giving the assignment with the theme of 'Nursing and Society' between peer mentors and mentees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second Session
Description: Training of peer mentors on communication techniques, interview methods and empathic approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Third session
Description: Sharing postcasts on communication techniques, interview methods and empathic approach with peer mentors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fourth session
Description: Training of peer mentors on social motivation and leader-member interaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fifth Session
Description: Sharing postcasts with peer mentors on social motivation and leader-member interaction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sixth Session
Description: Presentation of 'Nursing and Society' themed assignments of peer mentors and mentees as a group (Composition, poem, poster, presentation, role play, etc. are left free among the students) and post-test application.